Kodiak Sciences Inc.

103 articles with Kodiak Sciences Inc.

• Kodiak Sciences to Present at Upcoming Conferences - Sep 02, 2020

  9/2/2020

  Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that management will present at the following upcoming virtual investor conferences:

• Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights

  8/10/2020

  Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, reported business highlights and financial results for the second quarter ended June 30, 2020.

• Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress

  7/16/2020

  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D Webcast for investors and analysts on Monday, July 27 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

• Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar

  7/7/2020

  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming America

• Kodiak Sciences to Present at Upcoming Conferences - May 28, 2020

  5/28/2020

  Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that management will present at the following upcoming virtual investor conferences

• Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights

  5/11/2020

  Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the first quarter ended March 31, 2020.

• Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference

  5/11/2020

  Kodiak Sciences Inc., a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that management will present at the virtual Bank of America Merrill Lynch Health Care Conference on Wednesday, May 13, 2020 at 11:20 a.m. Pacific Time.

• Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020

  5/8/2020

  Kodiak Sciences Inc., a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that it will host a business highlights webcast on Tuesday, May 12, 2020 at 1:30 p.m. Pacific Time.

• Kodiak Sciences Appoints Charles Bancroft to Board of Directors

  4/2/2020

  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.

• "Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use

  3/24/2020

  Kodiak Sciences Inc. announced that the company received full registration of their trademarks "Kodiak" and "Kodiak Sciences" from the U.S. Patent and Trademark Office for the exclusive use of Kodiak Sciences Inc. and its subsidiaries.

• Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

  3/16/2020

   Kodiak Sciences Inc. today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019 .

• Kodiak Sciences to Present at Upcoming Conferences

  2/27/2020

  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:

• 

  Clinical Catch-Up: February 10-14

  2/17/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: February 3-7, 2020

  2/10/2020

  Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.

• Kodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion

  2/8/2020

  Encouraging safety profile continues with zero cases of intraocular inflammation after 420 doses in 130 patients

• Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting

  2/5/2020

  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study data on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2020 meeting being held on February 8, 2020, in Miami, Florida.

• Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference

  1/8/2020

  Kodiak Sciences Inc. announced that management will present a company overview at the J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2020 at 7:30 a.m. Pacific Time.

• Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors

  12/19/2019

   Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to its board of directors.

• StartX Med’s First Billion Dollar Biotech Company, Kodiak Sciences, Reaches a $3.56B Market Cap

  12/9/2019

  StartX Med company Kodiak Sciences, a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases, recently reached a market cap of $3.56 billion.

• Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  12/6/2019

  Kodiak Sciences Inc. (Nasdaq: KOD), today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes 900,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $46.00 per share.